Doxribtimine
As of the edition of 20 October 2026, Doxribtimine is a small molecule: marketed, first approved in 2025 (US); no US protection is listed.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2026
- Kind
- Small molecule
- Brand name
- Kygevvi
- First approved
- 3 November 2025 (US)
- Approvals on record
- 2 in 2 regions
- Holder of the most recent approval
- UCB; 2 holders in all
- Registered trials
- 8, 1 stopped early
- Disease areas
- Bones, joints and muscles; Nervous system; Nutrition and metabolism; Inherited and neonatal; Blood and lymph; Digestive system
US protection
No US protection is listed.
The FDA registers list no drug-substance patent or exclusivity that counts for this drug.
This is the US only.
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 2 | 1 | 0 | 0 |
| Phase 1 | 1 | 0 | 1 | 0 |
| Phase 2 | 4 | 2 | 2 | 0 |
| Phase 3 | 1 | 0 | 0 | 1 |
| All trials | 8 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| UCB | Originator and Lead sponsor of trials | 2026 to now |